Genmab A/S Share Capital Reduction

Company Announcement - Genmab A/S has decided to reduce its share capital by DKK 2,076,853 through the cancellation of 2,076,853 shares with a nominal value of DKK 1 each [1] - The share capital reduction has been registered with the Danish Business Authority and is expected to be updated in Nasdaq's system by April 14, 2025 [1] - After the reduction, Genmab's total nominal share capital will be DKK 64,120,391, consisting of 64,120,391 shares, each with a nominal value of DKK 1 [1] About Genmab - Genmab is an international biotechnology company focused on improving patient lives through innovative antibody therapeutics [2] - The company has developed next-generation antibody technology platforms and has a proprietary pipeline that includes bispecific T-cell engagers and antibody-drug conjugates [2] - Genmab aims to transform the lives of people with cancer and other serious diseases with its KYSO antibody medicines by 2030 [2] Company Background - Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with a presence in North America, Europe, and Asia Pacific [3]